Peter Lawson
Stock Analyst at Barclays
(2.07)
# 3,056
Out of 5,237 analysts
103
Total ratings
41.11%
Success rate
-6.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines AG | Maintains: Overweight | $405 → $409 | $310.75 | +31.62% | 4 | May 7, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $19 → $22 | $21.38 | +2.90% | 5 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $90 → $101 | $100.32 | +0.68% | 1 | Oct 29, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $28.13 | +42.20% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $12.72 | +96.54% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $3.74 | -19.79% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $49.71 | -19.53% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $2.95 | +1.69% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $2.18 | -8.26% | 4 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $8.81 | +13.51% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $3.70 | +8.11% | 7 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $22 → $6 | $12.79 | -53.09% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $52 | $28.85 | +80.24% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $9.51 | +15.67% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $9.66 | +65.63% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $4.70 | +219.15% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $24.86 | -43.68% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.57 | +91.08% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.18 | +154.24% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.39 | +187.77% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $144.15 | -58.38% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $12.85 | +32.30% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $16.28 | +90.42% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $23.48 | -44.63% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $4.80 | +4.17% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $3.86 | -9.33% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $142.51 | +156.12% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $27.99 | +64.34% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $78.72 | +471.65% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $3.06 | +1,370.59% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $54.01 | -16.68% | 2 | Jan 23, 2018 |
BeOne Medicines AG
May 7, 2026
Maintains: Overweight
Price Target: $405 → $409
Current: $310.75
Upside: +31.62%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $19 → $22
Current: $21.38
Upside: +2.90%
Incyte
Oct 29, 2025
Maintains: Overweight
Price Target: $90 → $101
Current: $100.32
Upside: +0.68%
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $28.13
Upside: +42.20%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $12.72
Upside: +96.54%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $3.74
Upside: -19.79%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $49.71
Upside: -19.53%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $2.95
Upside: +1.69%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $2.18
Upside: -8.26%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $8.81
Upside: +13.51%
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $3.70
Upside: +8.11%
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $12.79
Upside: -53.09%
May 7, 2025
Maintains: Overweight
Price Target: $66 → $52
Current: $28.85
Upside: +80.24%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $9.51
Upside: +15.67%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $9.66
Upside: +65.63%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $4.70
Upside: +219.15%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $24.86
Upside: -43.68%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.57
Upside: +91.08%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.18
Upside: +154.24%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.39
Upside: +187.77%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $144.15
Upside: -58.38%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $12.85
Upside: +32.30%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $16.28
Upside: +90.42%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $23.48
Upside: -44.63%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $4.80
Upside: +4.17%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $3.86
Upside: -9.33%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $142.51
Upside: +156.12%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $27.99
Upside: +64.34%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $78.72
Upside: +471.65%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $3.06
Upside: +1,370.59%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $54.01
Upside: -16.68%